...
首页> 外文期刊>The Journal of toxicological sciences >Detection of metabolic activation leading to drug-induced phospholipidosis in rat hepatocyte spheroids
【24h】

Detection of metabolic activation leading to drug-induced phospholipidosis in rat hepatocyte spheroids

机译:检测代谢活化导致药物诱导的大鼠肝细胞球体磷脂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Drug-induced phospholipidosis (PLD) is one of the adverse reactions to treatment with cationic amphiphilic drugs. Recently, simple and reliable evaluation methods for PLD have been reported. However, the predictive power of these methods for in vivo PLD induction is insufficient in some cases. To accurately predict PLD, we focused on drug metabolism and used three-dimensional cultures of hepatocytes known as spheroids. Here we used the fluorescent phospholipid dye N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE) to detect PLD induction. After 48 hr exposure to 20 μM amiodarone and amitriptyline, PLD inducers, NBD-PE fluorescence in the spheroids was significantly higher than that in the control. In contrast, 1 mM acetaminophen, as a negative control, did not increase fluorescence. Furthermore, the combination of NBD-PE fluorescence and LysoTracker Red fluorescence and the accumulation of intrinsic phospholipids reflected PLD induction in spheroids. To evaluate metabolic activation, we assessed PLD induction by loratadine. NBD-PE fluorescence intensity was significantly increased by 50 μM loratadine treatment. However, the fluorescence was markedly decreased by co-treatment with 500 μM 1-aminobenzotriazole, a broad cytochrome P450 inhibitor. The formation of desloratadine, a metabolite of loratadine, was observed in spheroids after treatment with loratadine alone. These results showed that metabolic activation is the key factor in PLD induction by treatment with loratadine. We demonstrated that rat primary hepatocyte spheroid culture is a useful model for evaluating drug-induced PLD induction mediated by metabolic activation of the drug using the fluorescence probe technique.
机译:药物诱发的磷脂酰肌病(PLD)是使用阳离子两亲药物治疗的不良反应之一。最近,已经报道了用于PLD的简单和可靠的评估方法。但是,在某些情况下,这些方法对体内PLD诱导的预测能力不足。为了准确预测PLD,我们专注于药物代谢,并使用了称为球体的肝细胞三维培养。在这里我们使用了荧光磷脂染料N-(7-硝基苯-2-氧杂-1,3-二唑-4-基)-1,2-二十六烷酰基-sn-甘油-3-磷酸乙醇胺(NBD-PE)检测PLD感应。暴露于20μM胺碘酮和阿米替林,PLD诱导剂,球体中的NBD-PE荧光48小时后,对照组显着升高。相反,作为阴性对照的1 mM对乙酰氨基酚没有增加荧光。此外,NBD-PE荧光和LysoTracker Red荧光的结合以及固有磷脂的积累反映了球体中的PLD诱导。为了评估代谢激活,我们评估了氯雷他定对PLD的诱导作用。 50μM氯雷他定治疗后NBD-PE荧光强度显着增加。但是,通过与500μM1-氨基苯并三唑(一种广泛的细胞色素P450抑制剂)共同处理,荧光显着降低。单独使用氯雷他定治疗后,在球体中观察到了氯雷他定的代谢产物地氯雷他定的形成。这些结果表明,通过氯雷他定治疗,代谢激活是诱导PLD的关键因素。我们证明大鼠原代肝细胞球体培养是一种有用的模型,用于评估使用荧光探针技术通过药物的代谢活化介导的药物诱导的PLD诱导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号